Home > News > The immune system in atherosclerosis and in acute myocardial infarction
Atherosclerosis
Read Time: < 1 min

The immune system in atherosclerosis and in acute myocardial infarction

Published Online: July 26th 2018 Heart International 2006;2(3-4):129-135
Authors: Matteo Vercellino, Patrizia Fabbi, Massimiliano Fedele, Francesco Indiveri, Antonio Barsotti
Quick Links:
Article
Article Information
Article:
Article Information:
Correspondence

Antonio Barsotti, DIMI – Division of Cardiology, V.le Benedetto XV, 6, 16132 Genova – Italy, Antonio.Barsotti@unige.it

Acknowledgements

The authors wish to thank Fondazione CARIGE – Genova,
which supported the project “Autoimmunity and
mechanisms of atherosclerotic plaque instability (AIMA)”.

Further Resources

Share this Article
Related Content In Atherosclerosis
Atherosclerosis, Cardiovascular Disease
generic_9.png
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Justin T Morrison, Judith Hsia, Marc P Bonaca Read Time: 14 mins

Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14

Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]

Atherosclerosis, Cardiovascular Disease
The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
Suvasini Lakshmanan, Matthew J Budoff Read Time: 12 mins

Heart International. 2021;15(1):7-13 DOI: https://doi.org/10.17925/HI.2021.15.1.7

There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for atherosclerotic cardiovascular disease (ASCVD). However, substantial residual cardiovascular (CV) risk remains, and there is an unmet need to reduce the residual risk of cardiovascular disease (CVD) events.1 There is increased focus on the role […]

Atherosclerosis
Use of Coronary Computed Tomography for Calcium Screening of Atherosclerosis
Joshua Beverly, Matthew J Budoff Read Time: 8 mins

Heart International. 2020;14(2):76-9 DOI: https://doi.org/10.17925/HI.2020.14.2.76

Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable to atherosclerosis.2 Moreover, the degree of coronary calcification strongly correlates with the magnitude of atherosclerotic plaque burden, […]

Trending In Atherosclerosis:

Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Atherosclerosis, Cardiovascular Disease
    • Download PDF More Actions
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72